Research Interests

• His laboratory and colleagues used genetic screens to identify potential targets and powerful drug combinations for the treatment of liver cancer. They identified CDK7 and CDK12 as potential therapeutic targets for advanced liver cancer (Cell Research 2018，Gut 2020). His finding revealed that the combination of a MEK inhibitor and sorafenib was effective for the MAPK activated advanced liver cancer (Journal of Hepatology 2018). His recent work highlights the potential of targeting ATR-CHK1 signaling, either alone or in combination with CDC7 inhibition based on the level of replication stress, for the treatment of liver cancer (Genome Medicine 2021). In addition, his recent work has proposed a “one-two punch” approach to cancer therapy in which the first drug induces a vulnerability based on senescence induction which can be exploited by the second drug (Nature 2019). Cun Wang was selected as an Editor-in-Chief for Cellular Oncology in 2022.